Vanguard Group’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,491,109
| Closed | -$5.68M | – | 4396 |
|
|
2024
Q2 | $5.68M | Buy |
2,491,109
+409,536
| +20% | +$1.56M | ﹤0.01% | 3204 |
|
|
2024
Q1 | $8.99M | Buy |
2,081,573
+99,900
| +5% | +$348K | ﹤0.01% | 3021 |
|
|
2023
Q4 | $6.04M | Buy |
1,981,673
+31,605
| +2% | +$59.4K | ﹤0.01% | 3207 |
|
|
2023
Q3 | $2.81M | Hold |
1,950,068
| – | – | ﹤0.01% | 3477 |
|
|
2023
Q2 | $4.86M | Sell |
1,950,068
-40,707
| -2% | -$111K | ﹤0.01% | 3316 |
|
|
2023
Q1 | $5.34M | Buy |
1,990,775
+64,930
| +3% | +$312K | ﹤0.01% | 3279 |
|
|
2022
Q4 | $10.5M | Buy |
1,925,845
+239,392
| +14% | +$2.01M | ﹤0.01% | 2930 |
|
|
2022
Q3 | $21.1M | Buy |
1,686,453
+65,952
| +4% | +$753K | ﹤0.01% | 2598 |
|
|
2022
Q2 | $8.01M | Sell |
1,620,501
-303,203
| -16% | -$1.68M | ﹤0.01% | 3106 |
|
|
2022
Q1 | $14.6M | Sell |
1,923,704
-620,661
| -24% | -$5.89M | ﹤0.01% | 2948 |
|
|
2021
Q4 | $26M | Buy |
2,544,365
+38,297
| +2% | +$488K | ﹤0.01% | 2699 |
|
|
2021
Q3 | $33.6M | Buy |
2,506,068
+3,242
| +0.1% | +$52.8K | ﹤0.01% | 2580 |
|
|
2021
Q2 | $54.9M | Buy |
2,502,826
+61,841
| +3% | +$1.37M | ﹤0.01% | 2318 |
|
|
2021
Q1 | $58.7M | Buy |
2,440,985
+345,258
| +16% | +$8.02M | ﹤0.01% | 2230 |
|
|
2020
Q4 | $37.7M | Buy |
2,095,727
+76,307
| +4% | +$1.14M | ﹤0.01% | 2345 |
|
|
2020
Q3 | $23.3M | Sell |
2,019,420
-37,791
| -2% | -$624K | ﹤0.01% | 2386 |
|
|
2020
Q2 | $49.9M | Buy |
2,057,211
+8,124
| +0.4% | +$134K | ﹤0.01% | 2015 |
|
|
2020
Q1 | $22.6M | Buy |
2,049,087
+35,522
| +2% | +$663K | ﹤0.01% | 2229 |
|
|
2019
Q4 | $53.2M | Buy |
2,013,565
+21,222
| +1% | +$496K | ﹤0.01% | 2082 |
|
|
2019
Q3 | $45.4M | Buy |
1,992,343
+15,728
| +0.8% | +$496K | ﹤0.01% | 2116 |
|
|
2019
Q2 | $60.6M | Buy |
1,976,615
+100,523
| +5% | +$2.12M | ﹤0.01% | 1998 |
|
|
2019
Q1 | $31.1M | Buy |
1,876,092
+176,440
| +10% | +$3.35M | ﹤0.01% | 2304 |
|
|
2018
Q4 | $32.5M | Sell |
1,699,652
-18,081
| -1% | -$677K | ﹤0.01% | 2232 |
|
|
2018
Q3 | $89.8M | Buy |
1,717,733
+743,596
| +76% | +$40.5M | ﹤0.01% | 1865 |
|
|
2018
Q2 | $42.3M | Sell |
974,137
-30,694
| -3% | -$1.32M | ﹤0.01% | 2209 |
|
|
2018
Q1 | $37.2M | Buy |
1,004,831
+236,363
| +31% | +$6.31M | ﹤0.01% | 2219 |
|
|
2017
Q4 | $15.2M | Buy |
768,468
+528,757
| +221% | +$11.4M | ﹤0.01% | 2615 |
|
|
2017
Q3 | $5.97M | Buy |
239,711
+165,711
| +224% | +$3.06M | ﹤0.01% | 3046 |
|
|
2017
Q2 | $1.29M | Buy |
+74,000
| New | +$1.29M | ﹤0.01% | 3514 |
|
Vanguard Group's GTHX Position: Q3 2024 in Review
Vanguard Group sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 2,491,109 shares — an estimated $5.68M sold.
Vanguard Group first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $89.8M in Q3 2018. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Vanguard Group reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Vanguard Group sold 2,491,109 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $5.68M.
- Vanguard Group first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- Vanguard Group's G1 Therapeutics, Inc. Common Stock position peaked at $89.8M in Q3 2018.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.